SPDR S&P Biotech ETF Rating $155.38 +3.79 (+2.50%) As of 06/26/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Biotech ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.71Holdings in XBI have an aggregate rating of Moderate Buy based on 407 analyst ratings issued in the past year covering 25 companies (35.6% of the portfolio).XBI Aggregate Price Target$155.38High Prediction$155.38Average Prediction$155.38Low Prediction$155.38Holdings in XBI have an aggregate price target of $155.38 and a range of $155.38 to $155.38 covering 25 companies (35.6% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XBI Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.03%TGTXTG Therapeutics$55.83+4.1%2.9251 of 5 stars2.75$58.60 5.0%8Positive NewsHigh Trading Volume2.03%TVTXTravere Therapeutics$58.85-0.3%1.6911 of 5 stars2.69$52.08 -11.5%13Positive NewsAnalyst DowngradeHigh Trading Volume1.96%TWSTTwist Bioscience$99.84+3.3%1.2289 of 5 stars2.80$74.60 -25.3%10Analyst ForecastInsider TradeHigh Trading Volume1.77%ALKSAlkermes$55.08+4.3%1.6664 of 5 stars2.78$47.06 -14.6%18Positive NewsAnalyst ForecastHigh Trading Volume1.75%RVMDRevolution Medicines$182.08+2.2%1.6715 of 5 stars3.00$123.72 -32.1%22Insider TradeOptions VolumeHigh Trading Volume1.54%ARWRArrowhead Pharmaceuticals$78.89-0.5%2.0257 of 5 stars2.69$86.36 9.5%13Analyst UpgradeHigh Trading Volume1.48%KRYSKrystal Biotech$372.25+3.4%2.2241 of 5 stars2.83$340.56 -8.5%12Insider TradeHigh Trading Volume1.39%EXELExelixis$54.77+2.9%2.2336 of 5 stars2.30$46.87 -14.4%20Analyst ForecastHigh Trading Volume1.38%BEAMBeam Therapeutics$34.81+2.6%2.0662 of 5 stars2.71$46.83 34.5%14High Trading Volume1.36%CYTKCytokinetics$82.17+1.7%3.0596 of 5 stars2.86$100.20 21.9%22Analyst ForecastInsider TradeHigh Trading Volume1.36%NBIXNeurocrine Biosciences$168.52+2.6%4.42 of 5 stars2.96$187.52 11.3%23Positive NewsAnalyst Upgrade1.36%NUVLNuvalent$123.520.0%2.47 of 5 stars2.15$127.73 3.4%20Analyst DowngradeShort Interest Decrease1.32%PTCTPTC Therapeutics$84.43-0.1%2.3332 of 5 stars2.71$91.36 8.2%14News CoverageInsider Trade1.31%APGEApogee Therapeutics$132.55-0.1%1.3642 of 5 stars2.24$121.25 -8.5%21Analyst DowngradeInsider TradeOptions Volume1.31%VCYTVeracyte$60.49+3.3%1.6172 of 5 stars2.56$47.57 -21.4%9Analyst ForecastHigh Trading Volume1.28%MDGLMadrigal Pharmaceuticals$512.65-0.2%3.3737 of 5 stars2.78$687.93 34.2%18Analyst ForecastHigh Trading Volume1.28%PTGXProtagonist Therapeutics$121.88-0.6%0.9565 of 5 stars2.88$115.21 -5.5%16News CoverageAnalyst DowngradeInsider TradeHigh Trading Volume1.27%NTRANatera$261.91+0.4%1.8492 of 5 stars2.86$259.22 -1.0%22Analyst ForecastInsider TradeHigh Trading Volume1.23%MIRMMirum Pharmaceuticals$123.59+5.4%2.2567 of 5 stars2.93$139.80 13.1%15Analyst DowngradeHigh Trading Volume1.22%MRNAModerna$67.27+12.6%1.1187 of 5 stars1.83$37.13 -44.8%18Trending NewsAnalyst Forecast1.22%KYMRKymera Therapeutics$108.12-7.2%1.8899 of 5 stars2.96$118.18 9.3%23Trending NewsAnalyst ForecastInsider TradeGap DownHigh Trading Volume1.22%SYRESpyre Therapeutics$87.89-0.9%1.7857 of 5 stars3.00$95.83 9.0%13Analyst ForecastInsider TradeGap UpHigh Trading Volume1.20%SRRKScholar Rock$54.76+1.8%1.7335 of 5 stars3.12$56.00 2.3%17High Trading Volume1.18%RYTMRhythm Pharmaceuticals$109.84+1.5%2.5227 of 5 stars2.83$133.13 21.2%18Insider TradeHigh Trading Volume1.18%ARQTArcutis Biotherapeutics$27.00+1.2%3.2694 of 5 stars2.50$34.00 25.9%8Analyst ForecastHigh Trading Volume This page (NYSEARCA:XBI) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
